Evogene Ltd. announced positive initial clinical data for its microbiome-based therapy BMC128 from an ongoing Phase 1 trial in patients with non-small cell lung cancer, melanoma, or renal cell carcinoma on May 23, 2024. This event is significant for the company and has a positive sentiment from an equity investor perspective.